光动力疗法治疗非黑色素瘤皮肤癌的研究进展

doi:10.11904/j.issn.1002-3070.2016.01.015

摘要/Abstract

摘要：

非黑色素瘤皮肤癌是人类最常见的恶性肿瘤之一。其发病率最高的是基底细胞癌,其次为易发生转移的鳞状细胞癌。光动力疗法应用于人类肿瘤研究已经有三十多年的历史,作为一种非创伤性的治疗方法,它的优点是可以局部用药并保护治疗区域的美观性。在很多临床病例研究中,光动力疗法显示了其对非黑色素瘤皮肤癌的治疗作用。本文综述了光动力疗法治疗非黑色素瘤皮肤癌的现有研究成果,为其在临床应用提供参考依据。

关键词: 光动力疗法, 非黑色素瘤皮肤癌, 基底细胞癌, 鳞状细胞癌

Abstract:

Non-melanoma skin cancers(NMSC)are one of the most common malignancy in humans.Among NMSC types,basal cell carcinoma(BCC)has the highest incidence and squamous cell carcinoma(SCC)is less common although it can metastasize.Over 30 years ago,Photodynamic therapy(PDT)was applied for the study of human tumor,it showed the advantage of being a non-invasive option,and capable of field treatment,providing optimum cosmetic outcomes.Numerous clinical research studies have shown the efficacy of PDT for treating NMSC.The purpose of this systematic review is to summarize the previous Results,current evidence and the possibilities for PDT in patients with NMSC.

Key words: Photodynamic therapy, Non-melanoma skin cancer, Basal cell carcinoma, Squamous cell carcinoma

中图分类号:

R730.59

张嘉辉综述, 毕良佳审校. 光动力疗法治疗非黑色素瘤皮肤癌的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 71-74.

ZHANG Jiahui, BI Liangjia. Research advances in the treatment of non-melanoma skin cancer using photodynamic therapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 71-74.

参考文献

1 Eisemann N,Waldmann A,Geller AC,et al.Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence[J].Investig Dermatol,2014,134(1):43-50.
2 Koyuncuer A.Histopathological evaluation of non-melanoma skin cancer[J].World J Surg Oncol,2014,12(12):159-165.
3 Berking C,Hauschild A,Klbl O,et al.Basal cell carcinoma-treatments for the commonest skin cancer[J].Dtsch Arztebl Int,2014,111(22):389-395.
4 Martorell-Calatayud A,Sanmartín O,Cruz J,et al.Cutaneous squamous cell carcinoma:Defining the high-risk variant[J].Actas Dermosifiliogr,2013,104(5):367-379.
5 Mfouo-Tynga I,Abrahamse H.Cell death pathways and phthalocyanine as an efficient agent for photodynamic cancer therapy[J].Int J Mol Sci,2015,16(5):10228-10241.
6 Morton C,Szeimies RM,Sidoroff A,et al.European Dermatology Forum Guidelines on topical photodynamic therapy[J].Eur J Dermatol,2015,25(4):296-311.
7 Kauvar AN,Cronin T,Jr Roenigk R,et al.Consensus for nonmelanoma skin cancer treatment:Basal cell carcinoma,including a cost analysis of treatment methods[J].Dermatol Surg,2015,41(5):550-571.
8 Ferrándiz C,Fonseca-Capdevila E,García-Diez A,et al.Spanish adaptation of the European guidelines for the evaluation and treatment of actinic keratosis[J].Actas Dermosifiliogr,2014,105(4):378-393.
9 Steinbauer JM,Schreml S,Kohl EA,et al.Photodynamic therapy in dermatology[J].Dtsch Dermatol Ges,2010,8(6):454-464.
10 Choudhary S,Nouri K,Elsaie ML,et al.Photodynamic therapy in dermatology:A review[J].Lasers Med Sci,2009,24(6):971-980.
11 Blume JE,Oseroff AR.Aminolevulinic acid photodynamic therapy for skin cancers[J].Dermatol Clin,2007,25(1):5-14.
12 Evangelou G,Farrar MD,Cotterell L,et al.Topical photodynamic therapy significantly reduces epidermal Langerhans cells during clinical treatment of basal cell carcinoma[J].Br J Dermatol,2012,166(5):1112-1115.
13 Lu YG,Wang YY,Yang YD,et al.Efficacy of topical ALA-PDT combined with excision in the treatment of skin malignant tumor[J].Photodiagn Ther,2014,11(2):122-126.
14 Jeremic G,Brandt MG,Jordan K,et al.Using photodynamic therapy as a neoadjuvant treatment in the surgical excision of nonmelanotic skin cancers:Prospective study[J].Otolaryngol Head Neck Surg,2011,40(1):82-89.
15 Sotiriou E,Lallas A,Apalla Z,et al.Treatment of giant Bowen′s disease with sequential use of photodynamic therapy and imiquimod cream[J].Photodermatol Photoimmunol Photomed,2011,27(3):164-166.
16 Cai H,Wang YX,Zheng JC,et al.Photodynamic therapy in combination with CO₂ laser for the treatment of Bowen′s disease[J].Lasers Med Sci,2015,30(5):1505-1510.
17 Rollakanti K,Anand S,Maytin EV,et al.Topical calcitriol prior to photodynamic therapy enhances treatment efficacy in non-melanoma skin cancer mouse models[J].Proc SPIE Int Soc Opt Eng,2015,2(2):1-13.
18 Torres T,Fernandes I,Costa V,et al.Photodynamic therapy as adjunctive therapy for morpheaform basal cell carcinoma[J].Acta Dermatovenerol Alp Pannonica Adriat,2011,20(1):23-25.
19 Osiecka B,Jurczyszyn K,Ziólkowski P,et al.The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma[J].Med Sci Monit,2012,18(2):5-9.
20 Requena C,Messeguer F,Llombart B,et al.Facial extensive recurrent basal cell carcinoma:Successful treatment with photodynamic therapy and imiquimod 5% cream[J].Int J Dermatol,2012,51(4):451-454.
21 Smucler R,Vlk M.Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma[J].Lasers Surg Med,2008,40(2):153-158.
22 Shokrollahi K,Javed M,Aeuyung K,et al.Combined carbon dioxide laser with photodynamic therapy for nodular and superficial basal cell carcinoma[J].Ann Plast Surg,2014,73(5):552-558.
23 Kasche A,Luderschmidt S,Ring J,et al.Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid[J].J Drugs Dermatol,2006,5(4):353-356.
24 Morton CA,Szeimies RM,Sidoroff A,et al.European guidelines for topical photodynamic therapy part 1:Treatment delivery and current indications-actinic keratoses,Bowen′s disease,basal cell carcinoma[J].J Eur Acad Dermatol Venereol,2013,27(5):536-544.
25 Braathen LR,Szeimies RM,Basset-Seguin N,et al.Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer:An international consensus[J].Am Acad Dermatol,2007,56(1):125-143.
26 Roozeboom MH,van Kleef L,Arits AH,et al.Tumor thickness and adnexal extension of superficial basal cell carcinoma(sBCC)as determinants of treatment failure for methyl aminolevulinate(MAL)-photodynamic therapy(PDT),imiquimod,and 5-fluorouracil(FU)[J].Am Acad Dermatol,2015,73(1):93-98.
27 Christensen E,Mrk C,Foss OA,et al.Pre-treatment deep curettage can significantly reduce tumour thickness in thick basal cell carcinoma while maintaining a favourable cosmetic outcome when used in combination with topical photodynamic therapy[J].Skin Cancer,2011,240(6):1-6.
28 Nissen CV,Philipsen PA,Wulf HC,et al.PpIX formation after topical application of methyl aminolevulinate and BF-200 ALA declines with age[J].Br J Dermatol,2015,173(3):760-766.
29 Vinciullo C,Elliott T,Francis D,et al.Photodynamic therapy with topical methyl aminolaevulinate for “difficult-to-treat” basal cell carcinoma[J].Br J Dermatol,2005,152(4):765-772.

[1]	王蕾, 姜寰宇, 宋凯镔. miR-219调控PRKCI表达在舌鳞状细胞癌中作用和机制[J]. 实用肿瘤学杂志, 2018, 32(6): 510-514.
[2]	郝贺, 李幸, 吴玲彦, 郭晓金, 曹静, 杨春旺, 张晓, 汪治宇. PD-1、CTLA-4、BLTA在食管鳞状细胞癌患者外周血中的表达及临床意义[J]. 实用肿瘤学杂志, 2018, 32(4): 303-308.
[3]	李宏伟, 蒋小凤, 陈松, 别一非, 杜勇. 头部巨大瘢痕鳞状细胞癌伴颅骨、硬脑膜侵犯一例[J]. 实用肿瘤学杂志, 2018, 32(4): 337-339.
[4]	杜灵彬, 魏文强. 中国人群食管鳞癌生存分析研究新进展[J]. 实用肿瘤学杂志, 2018, 32(4): 344-348.
[5]	李宏伟, 刘川, 王朗, 刘竣, 杨汉丰, 杜勇. 光动力疗法在消化道恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 77-81.
[6]	周军敏, 戴绍春, 周森. 5-氨基酮戊酸光动力疗法联合重组人干扰素α2b软膏治疗老年患者表浅基底细胞癌的临床观察[J]. 实用肿瘤学杂志, 2016, 30(5): 396-399.
[7]	苑振楠, 宋凯镔. miR-219在舌鳞状细胞癌中的表达及意义研究[J]. 实用肿瘤学杂志, 2016, 30(5): 420-424.
[8]	纪雪钰, 臧立新, 王月萍, 孟培松. 芦荟大黄素介导的光动力疗法对人口腔黏膜癌KB细胞杀伤效果的研究[J]. 实用肿瘤学杂志, 2016, 30(3): 220-224.
[9]	刘冰梅, 夏丽杰, 刘忆梅, 杨晶. 皮肤鳞状细胞癌研究进展[J]. 实用肿瘤学杂志, 2015, 29(6): 545-548.
[10]	刘冰梅, 杨晶, 张翰文, 邢荣贵, 李丽丽, 赵丽萍, 乔适, 尤海燕. 角化棘皮瘤与高分化鳞状细胞癌细胞周期和细胞凋亡相关蛋白表达的研究[J]. 实用肿瘤学杂志, 2014, 28(6): 485-491.
[11]	宁四清, 詹波涛, 徐海声. TNP方案在头颈部鳞状细胞癌中的疗效探讨[J]. 实用肿瘤学杂志, 2014, 28(6): 540-544.
[12]	修骋, 杨宪广, 裴荣, 孙冀. Kiss-1和E-cadherin在声门上型喉鳞状细胞癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2013, 27(4): 334-339.
[13]	何国庆, 管强, 张喜军, 张杰武, 姬宏飞. p21活化蛋白激酶1对喉癌细胞运动侵袭能力的影响[J]. 实用肿瘤学杂志, 2012, 26(6): 501-505.
[14]	何国庆, 管强, 张喜军, 张杰武, 姬宏飞, 徐晋. 喉癌中PAK1基因mRNA的表达及临床意义[J]. 实用肿瘤学杂志, 2012, 26(5): 410-413.
[15]	高红军, 岳志刚, 周艳秋, 许慧, 段志玲, 郑朝旭. 肿瘤相关抗原HSC70在食管癌中的鉴定与表达研究[J]. 实用肿瘤学杂志, 2012, 26(2): 137-140.